Evidax

Evidax generates comparative evidence that gets a rare disease treatment reimbursed in multiple markets. Most orphan drugs do not have it because their pivotal trial is single-arm. From 2028, orphan drug developers will have 100 days to submit it for the EU Joint Clinical Assessment. We build the comparative evidence from external data sources in 14 days, to the standard HTA bodies accept.